Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04941287
Title Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of A Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

intrahepatic cholangiocarcinoma

biliary tract cancer

gallbladder carcinoma


Atezolizumab + Varlilumab

Atezolizumab + Cobimetinib + Varlilumab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.